Institutional investors
Biotech Investor · 27 portfolio companies
Portfolio
27
Combined Value
$8758.4B
Focus Areas
67
Top Stage
Commercial
Investment Focus
Portfolio Companies
| Company | Valuation |
|---|---|
| Sun Pharmaceutical | $4248.3B |
| Cipla | $1017.8B |
| Aurobindo Pharma | $750.4B |
| Glenmark Pharmaceuticals | $615.4B |
| Johnson & Johnson | $567.2B |
| Jiangsu Hengrui Medicine | $366.0B |
| AbbVie | $362.6B |
| Pfizer | $153.4B |
| Vertex Pharmaceuticals | $115.4B |
| GSK plc | $104.1B |
| Regeneron Pharmaceuticals | $77.5B |
| CSL | $67.2B |
| Zoetis | $51.0B |
| Alnylam Pharmaceuticals | $41.4B |
| Argenx | $41.1B |
| Bayer | $37.7B |
| Teva Pharmaceutical Industries | $33.5B |
| Royalty Pharma | $26.2B |
| United Therapeutics | $23.0B |
| Neurocrine Biosciences | $12.8B |
| Elanco | $11.9B |
| Dr. Reddy's Laboratories | $11.5B |
| Jamjoom Pharmaceuticals Factory Company | $9.7B |
| Charles River Laboratories | $7.6B |
| Amicus Therapeutics | $4.5B |
| Harrow Health | $1.2B |
| Seres Therapeutics | $76.9M |